Leptin replacement therapy in the management of lipodystrophy syndromes.
Ann Endocrinol (Paris)
; 85(3): 201-204, 2024 Jun.
Article
en En
| MEDLINE
| ID: mdl-38871500
ABSTRACT
Lipodystrophy syndromes are rare diseases of genetic or acquired origin, characterized by quantitative and qualitative defects in adipose tissue. The metabolic consequences of lipodystrophy syndromes, such as insulin resistant diabetes, hypertriglyceridemia and hepatic steatosis, are frequently very difficult to treat, resulting in significant risks of acute and/or chronic complications and of decreased quality of life. The production of leptin by lipodystrophic adipose tissue is decreased, more severely in generalized forms of lipodystrophy, where adipose tissue is absent from almost all body fat depots, than in partial forms of the disease, where lipoatrophy affects only some parts of the body and can be associated with increased body fat in other anatomical regions. Several lines of evidence in preclinical and clinical models have shown that leptin replacement therapy could improve the metabolic complications of lipodystrophy syndromes. Metreleptin, a recombinant leptin analogue, was approved as an orphan drug to treat the metabolic complications of leptin deficiency in patients with generalized lipodystrophy in the USA or with either generalized or partial lipodystrophy in Japan and Europe. In this brief review, we will discuss the benefits and limitations of this therapy, and the new expectations arising from the recent development of a therapeutic monoclonal antibody able to activate the leptin receptor.
Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Terapia de Reemplazo de Hormonas
/
Leptina
/
Lipodistrofia
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Ann Endocrinol (Paris)
Año:
2024
Tipo del documento:
Article